Skip to main content
TipRanks
Go Ultimate75% OFF

Nureca Ltd. (NURECA) AI Stock Analysis

0 Followers
IN:NURECA

Nureca Ltd.

(NSE:NURECA)

Select Model
Rating:58Neutral
Price Target:INR 322.00â–²(3.95% Upside)
Action:reiterated
Date:09/29/26

The overall score of 58 reflects a company in the early stages of a financial turnaround, supported by a very strong balance sheet. The primary positive driver is the bullish technical momentum, indicating market confidence in the recovery. However, this is significantly offset by an extremely high valuation (P/E of 88.5) and the company's currently thin profitability and fragile cash flows, which present substantial risk if the growth trajectory falters.

Positive Factors
Conservative Balance SheetThe very low debt-to-equity ratio and large equity base reduce financial strain and preserve capacity to fund operations or growth without heavy reliance on borrowing. This conservative funding profile is particularly valuable while earnings remain volatile, because it improves resilience and keeps strategic options open.
Negative Factors
Thin Profit MarginsThin net and operating margins leave limited room to absorb cost increases, pricing pressure, or execution setbacks while still protecting earnings. The sharp decline from stronger FY2021–FY2022 profitability also suggests that the current recovery has not yet restored a robust or consistently scalable earnings model.

Nureca Ltd. (NURECA) vs. iShares MSCI India ETF (INDA)

-20%-10%0%10%20%30%40%50%IN:NURECA+21.57%INDA-2.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 3.13B
Dividend Yield
―
Average Volume (3M)
878
Price to Earnings (P/E)
66.0
Beta (1Y)
0.79
Revenue Growth
33.66%
EPS Growth
17.10%
Country
India
Employees
154
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Nureca Ltd. Business Overview & Revenue Model

Company Description

Operating in India, Nureca Limited is a business-to-consumer (B2C) firm specializing in home healthcare and general wellness solutions. Their extensive product portfolio addresses various health needs, encompassing items for managing chronic conditio...

Nureca Ltd. Financial Statement Overview

Summary

Nureca is showing a recovery with two years of revenue growth and a return to profitability. However, net margins remain very thin at 1.4% and cash flow, while improved, is still fragile. The strong, debt-light balance sheet is a major positive, but overall financial health is tempered by low profitability and historically volatile cash generation.

Income Statement

48Neutral

Balance Sheet

82Very Positive

Cash Flow

42Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue1.74B1.47B1.10B919.28M1.11B2.56B
Gross Profit444.82M352.34M231.33M311.42M355.94M1.23B
EBITDA111.18M85.19M48.95M2.41M-79.04M632.04M
Net Income47.60M20.82M8.46M-17.94M-82.50M449.60M
Balance Sheet
Total Assets2.31B1.96B2.10B2.05B2.07B2.19B
Cash, Cash Equivalents and Short-Term Investments735.52M424.31M736.29M1.44B1.02B927.10M
Total Debt66.01M22.59M49.66M25.16M33.27M44.05M
Total Liabilities433.97M153.96M156.91M120.54M116.97M159.32M
Stockholders Equity1.88B1.81B1.94B1.93B1.95B2.03B
Cash Flow
Free Cash Flow017.45M-234.06M-37.98M98.31M-46.00M
Operating Cash Flow085.74M-190.83M-27.12M102.27M13.99M
Investing Cash Flow081.20M84.39M175.76M-164.56M-30.89M
Financing Cash Flow0-184.66M-1.69M-13.03M-15.07M-73.02M

Nureca Ltd. Technical Analysis

Technical Analysis SentimentPositive
Last Price309.75

Price Trends

50DMA323.72Negative
100DMA312.41Negative
200DMA286.84Positive

Market Momentum

MACD-6.17Negative
RSI49.93Neutral
STOCH49.95Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NURECA, the sentiment is Positive. The current price of 309.75 is above the 20-day moving average (MA) of 304.15, below the 50-day MA of 323.72, and above the 200-day MA of 286.84, indicating a neutral trend. The MACD of -6.17 indicates Negative momentum. The RSI at 49.93 is Neutral, neither overbought nor oversold. The STOCH value of 49.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NURECA.

Nureca Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IN:NURECA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:BLUEJETIN:BLUEJET71OutperformINR 97.94B32.35―0.23%-7.05%-21.25%
IN:PGHLIN:PGHL64NeutralINR 93.00B24.43―3.77%16.05%23.81%
IN:AMRUTANJANIN:AMRUTANJAN62NeutralINR 14.94B25.86―0.96%12.56%1.03%
IN:NURECAIN:NURECA58NeutralINR 2.96B65.96――33.66%17.10%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IN:ZOTAIN:ZOTA45NeutralINR 39.07B-38.40―0.08%68.95%-55.82%

* Healthcare Sector Average

Performance Comparison

-40%-20%0%20%40%IN:NURECAIN:AMRUTANJANIN:BLUEJETIN:PGHLIN:SANOFICONRIN:ZOTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:NURECA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:NURECANureca Ltd.309.7556.7522.43%
IN:AMRUTANJANAmrutanjan Health Care Limited510.95-172.04-25.19%
IN:BLUEJETBlue Jet Healthcare Limited517.45-25.16-4.64%
IN:PGHLProcter & Gamble Health Ltd.5602.70-58.88-1.04%
IN:SANOFICONRSanofi Consumer Healthcare India Limited3449.50-1294.14-27.28%
IN:ZOTAZota Health Care Ltd.1288.00-339.28-20.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 29, 2026